Skip to main content
Caplight Logo









REGEnLIFE

REGEnLIFE

Private
ParisHealthcare & Life Scienceshttps://regenlife.com/

Last Round

Series A

May 9, 2023

Total Funding Raised

$6.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

REGEnLIFE is a therapeutic devices company that develops a non-invasive medical device designed to alter the progression of neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

photobiomodulationAlzheimer's disease treatmentPBMmedical deviceneurodegenerative diseasenon-invasive therapylight therapybrain-gut axisneuroinflammationwearable medical devicelow-level light therapynon-pharmacological treatmentbrain stimulationclinical trialsconcussion treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

REGEnLIFE Comparables

Compare REGEnLIFE with similar companies based on industry and business-model similarity.

REGEnLIFE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuroEM Therapeutics
81%
Neurocia SAS
80%
Cognito Therapeutics
79%

REGEnLIFE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 9, 2023
SeedJul 10, 2019

Key People

Founding team and executive leadership

Guillaume Blivet

Chief Innovation Officer & Co-founder

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 50% MoM.

  • Jun 17, 2026

    Monthly visitors increased 52% MoM.

Recent news

Latest coverage and updates

  • hiresAug 22, 2026

    REGEnLIFE hired Volker Herrmann as Chief Executive Officer on Jul 15th '26.

  • expands_facilitiesAug 22, 2026

    REGEnLIFE expands facilities to Nantes, France, Western Europe, Europe.

REGEnLIFE Filings

Explore SEC and related filing metadata, where available.

REGEnLIFE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about REGEnLIFE's valuation, stock price, and market status.

Is REGEnLIFE a public or private company?

REGEnLIFE is a private company.

What is the current stock price of REGEnLIFE?

REGEnLIFE is a private company with no public stock price. No recent secondary market data is available.

How much is REGEnLIFE worth (valuation)?

Valuation information for REGEnLIFE is not publicly available.

Can I buy REGEnLIFE stock?

REGEnLIFE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was REGEnLIFE's last funding round?

REGEnLIFE's most recent funding round was Series A on May 9, 2023.

Who are the main investors in REGEnLIFE?

Investor information for REGEnLIFE is not publicly disclosed.

Will REGEnLIFE IPO soon?

No public IPO plans have been announced for REGEnLIFE.

How can I track REGEnLIFE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor REGEnLIFE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range9
Year Founded2016
Last FundingMay 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?